10x Genomics, Inc. (TXG) stock
TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30113% above fair value
$57.07+0.77 (+1.37%)
Close on Nov 18, 2026Market cap $7.44BP/E –Yield –
10x Genomics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
10x Genomics's free cash flow for the twelve months ending Sep 30, 2026 was $93.77M, up 14.8% year over year. For fiscal 2025 it was $130.12M. The highest annual figure on record is $130.12M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.12M | – |
| FY2024 | Dec 31, 2024 | -$5.73M | – |
| FY2023 | Dec 31, 2023 | -$63.80M | – |
| FY2022 | Dec 31, 2022 | -$165.27M | – |
| FY2021 | Dec 31, 2021 | -$122.65M | – |
| FY2020 | Dec 31, 2020 | -$254.56M | – |
| FY2019 | Dec 31, 2019 | -$8.12M | – |
| FY2018 | Dec 31, 2018 | -$82.69M | – |
| FY2017 | Dec 31, 2017 | -$14.46M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $14.86M | -65.1% |
| Q2 FY2026 | Jun 30, 2026 | $15.39M | -4.6% |
| Q1 FY2026 | Mar 31, 2026 | $24.52M | -24.4% |
| Q4 FY2025 | Dec 31, 2025 | $39.00M | – |
| Q3 FY2025 | Sep 30, 2025 | $42.53M | +139.6% |
| Q2 FY2025 | Jun 30, 2025 | $16.13M | +249.3% |
| Q1 FY2025 | Mar 31, 2025 | $32.46M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.46M | -142.4% |
| Q3 FY2024 | Sep 30, 2024 | $17.75M | – |
| Q2 FY2024 | Jun 30, 2024 | $4.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.64M | – |
| Q4 FY2023 | Dec 31, 2023 | $22.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$40.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$36.88M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.68M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.01M | – |
| Q3 FY2022 | Sep 30, 2022 | -$46.14M | – |
| Q2 FY2022 | Jun 30, 2022 | -$44.18M | – |
| Q1 FY2022 | Mar 31, 2022 | -$48.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$46.44M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.45M | – |
| Q1 FY2021 | Mar 31, 2021 | -$42.95M | – |
| Q4 FY2020 | Dec 31, 2020 | -$151.51M | -105318.1% |
| Q3 FY2020 | Sep 30, 2020 | -$56.14M | -6720.0% |
| Q2 FY2020 | Jun 30, 2020 | -$36.26M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.66M | – |
| Q4 FY2019 | Dec 31, 2019 | $144.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $848.00K | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.06M | – |
| Q1 FY2019 | Mar 31, 2019 | -$49.00K | – |
| Q4 FY2018 | Dec 31, 2018 | -$53.40M | – |
See a number that looks wrong?